This is a randomised double-blind placebo-controlled trial of L-serine in Hereditary Sensory
Neuropathy type 1 (HSN1) due to variants in SPTLC1/2 gene.
This is a single-centre study being conducted at the National Hospital for Neurology and
Neurosurgery, London UK.
The SENSE trial will test whether L-serine is an effective drug treatment to slow or stop
disease progression in HSN1 due to variants in the SPLTLC1 or SPTLC2 gene. The other aim is
to assess if Magnetic Resonance Imaging (MRI) can accurately detect the changes which occur
in the muscles of people who have HSN1.